Physician profile
Siyun Li
NPI 1902821366
$4,185.44
in general payments reported to CMS, 2019-2025
29 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $67.24 · 2021: $19.42 · 2022: $147 · 2023: $610 · 2024: $1,282 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,621 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,621.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.68 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $767.56 | 2022-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $465.16 | 2019-2025 | Crexont, Rytary |
| Sk Life Science, INC. | $304.15 | 2022-2025 | |
| Lilly USA, LLC | $243.83 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Celgene Corporation | $212.24 | 2023-2025 | Zeposia |
| Ucb, INC. | $187.52 | 2019-2025 | Nayzilam, Briviact |
| Biogen, INC. | $168.75 | 2020-2025 | Vumerity, Tysabri, Avonex |
| Eisai INC. | $127.51 | 2024-2025 | |
| Mdd US Operations, LLC | $118.37 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Novartis Pharmaceuticals Corporation | $114.64 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $84.96 | 2024-2025 | |
| Pfizer INC. | $69.19 | 2025 | |
| Allergan, INC. | $61.93 | 2019 | |
| Acadia Pharmaceuticals INC | $56.73 | 2022-2024 | Nuplazid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $55.98 | 2025 | Austedo Xr |
| Emd Serono, INC. | $53.62 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $47.78 | 2021-2024 | Zeposia |
| Kyowa Kirin, INC. | $33.39 | 2024 | Nourianz |
| Amgen INC. | $33.28 | 2019 | |
| Sunovion Pharmaceuticals INC. | $32.81 | 2019 | |
| Aucta Pharmaceuticals, INC. | $30.94 | 2025 | Motpoly Xr |
| Inspire Medical Systems, INC. | $24.97 | 2024 | Inspire |
| Genzyme Corporation | $20.42 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.36 | 2024 | Dysport |
| Amylyx Pharmaceuticals, INC. | $17.74 | 2023 | Relyvrio |
| Supernus Pharmaceuticals, INC. | $17.18 | 2019 | |
| Genentech USA, INC. | $16.64 | 2025 | Ocrevus Zunovo |
| Adamas Pharmaceuticals, INC. | $13.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siyun Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.